Advances in the use of alemtuzumab in CLL

Clinical Advances in Hematology and Oncology

Volumn 6, Issue 1, 2008, Pages 23-24

  Stilgenbauer, Stephan ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN; RITUXIMAB; CANCER ANTIBODY; CD52 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ARTICLE; B CELL LEUKEMIA; BRONCHOSPASM; CHILL; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REGIMEN; DRUG FEVER; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; HYPOTENSION; LEUKEMIA REMISSION; MONOTHERAPY; RIGOR; SHAKES; STEM CELL TRANSPLANTATION; DRUG EFFECT; REMISSION; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GLYCOPROTEINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; REMISSION INDUCTION;

EID: 41449083666     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Faderl S, Coutré S, Byrd JC, et al. The evolving role of alemtuzumab in management of patients with CLL. Leukemia. 2005; 19:2147-2152.
2. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003101:3413-3415.
3. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy ifor chronic lymphocytic leukemi. J Clin Oncol. 2007;25:5616-5623.
4. Kay NE, Rai KR, O'Brien S. Chronic lymphocytic leukemia: current and emerging treatment approaches. Clin Adv Hematol Oncol. 2006;4(11 suppl 22);1-10.
5. Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia. 2007;21:1885-1891.
6. Morrison VA, Peterson BL, Rai KR, Byrd JC, Larson RA. Alemtuzumab increases serious infections in patients with previously utreated chronic lymphocytic leukemia (CLL) receiving fludarabine-based therapy: a comparative analysis of 3 Cancer and Leukemia Group B studies (CALGB 9011, 9712, 19901). Blood. 2007;110(11): Abstract 756.